New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- New forms of older anti-cancer agent appear to enhance immune response to fight melanoma on February 19, 2019 at 10:31 pm
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they deve... […]
- Molecular Test That Predicts Immunotherapy Response For Kidney Cancer on February 19, 2019 at 10:04 pm
The first line of treatment for kidney cancer is immunotherapy using drugs such as PD-L1 checkpoint inhibitors. However, the procedure is expensive and helps only a subset of patients and for the majo... […]
- Anti-cancer immunotherapy could be used to fight HIV on February 19, 2019 at 10:29 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple t... […]
- New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy on February 19, 2019 at 9:31 am
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full p... […]
- Global Cancer Immunotherapy Market is Projected to Reach $170.70 Billion by 2028 on February 19, 2019 at 9:00 am
FREMONT, California, Feb. 19, 2019 /PRNewswire/ -- According to a new market intelligence report by BIS Research, titled "Global Cancer Immunotherapy Market - Analysis and Forecast, 2018-2028", the ma... […]
- Using anti-cancer immunotherapy to fight HIV on February 19, 2019 at 8:20 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on ... […]
- Immunotherapy could extend survival for patients with aggressive glioblastoma brain cancer on February 19, 2019 at 4:43 am
Sen. John McCain died after a short battle against glioblastoma brain cancer. Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025: Grand View Research, Inc. on February 19, 2019 at 2:52 am
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand ... […]
- Immunotherapy may help patients with the kind of cancer that killed John McCain on February 18, 2019 at 5:19 pm
Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of former Vice President Joe Biden — is among the deadliest of cancers, with a three-year ... […]
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches on February 15, 2019 at 6:16 am
Advances in immunotherapy are improving outcomes for patients with various cancers. In addition, the immunogenicity of breast cancer is leading to increasingly optimistic views on the use of immunothe... […]
via Bing News